MedTrace Logo

Trial of Hematopoietic Stem Cells in Acute Myocardial Infarction

NCT00984178 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2010-02-02

No results posted yet for this study

Summary

The aim of this study is to compare the effectiveness of four different strategies for preventing the ventricular postinfarction remodelling: 1) Conventional treatment for reperfunded extensive acute myocardial infarction, 2) Autologous bone marrow stem-cells intracoronary transplantation 3) mobilization of bone marrow stem-cells induced by granulocyte colony-stimulating factors (G-CSF); and 4) combined treatment (stem-cells transplantation plus mobilization with G-CSF).

Conditions

  • Reperfused Acute Myocardial Infarction

Interventions

OTHER

Granulocite Colony Stimulating Factor treatment (G-CSF)

G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days

OTHER

Bone marrow mononuclear cells

Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration

Sponsors & Collaborators

  • Hospital General Universitario Gregorio Marañon

    collaborator OTHER

  • TECAM Group

    lead NETWORK

Principal Investigators

  • Francisco Fernandez-Aviles, MD, PhD · Hospital General Universitario Gregorio Marañón

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2009-11-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00984178 on ClinicalTrials.gov